Introduction
With the introduction of high dose therapy/ autologous stem cell transplantation (HDT/ASCT) as well as novel agents (up-front), most multiple myeloma (MM) patients achieve a transient remission; however, the vast majority still experience a relapse within a median period of 3 years from diagnosis. 1 Thus, long-term follow-up studies in the setting of HDT/ASCT show that only a small fraction of MM patients (6-18%) remain ≥10-years relapse-free, and these are now considered as being operationally cured. [2] [3] [4] Interestingly, this is not restricted to patients in complete response (CR), since those that revert to a monoclonal gammopathy of undetermined significance (MGUS)-like profile may also achieve long-term disease control (LTDC), despite persistence of a residual M-component. 4 Recent clinical and molecular data suggests that some features may help to identify this group of LTDC-MM patients such as an evolving smoldering pattern, a gene expression profile (GEP) signature of MGUS and the CD2 molecular subtype. 5, 6 Altogether, these findings suggest that in addition to anti-myeloma therapy, other factors may play a critical role in disease control.
For decades, increasing evidence shows that in active MM the immune system is dysfunctional and impaired. [7] [8] [9] [10] Accordingly, B-cell precursors and normal-PCs are 4 compromised, and immune paresis is also a consistent finding in newly-diagnosed MM patients. 11 In turn, effector cells such as NK cells and cytotoxic CD8+ T-cells are expanded in both the bone marrow (BM) and peripheral blood (PB), but they are unable to control disease progression, suggesting a marked immunosuppressive microenvironment. 12, 13 Moreover, dendritic cells (DCs) have also been reported to be altered in MM, with reduction in circulating myeloid (m-DCs) and plasmacytoid-DC (pDCs), lower expression of co-stimulatory molecules and impaired induction of allogeneic T-cell responses. [14] [15] [16] Since these immune defects are invariably present in active MM, we hypothesized that the immune system may play a critical role in LTDC-MM patients. To explore this possibility, in the present study we compared the distribution of many different subsets of T-B -and NK-lymphocytes and DCs in both BM and PB of MM patients that achieved long term disease control (LTDC-MM) versus patients with newlydiagnosed MGUS and symptomatic myeloma (MM-s), as well as healthy adults (HA) of similar age.
Design and Methods

Patients, controls and samples
A total of 74 patients with plasma cell (PC) disorders were prospectively studied. The group under investigation was composed of myeloma patients that achieved long-term disease control (LTDC-MM), (n=28) defined as either: i) MM patients achieving CR after up-front therapy and remaining for >5 years relapse-free (n=11), and ii) patients achieving near CR or partial response and remaining progression-free for ≥ 3 years without therapy (n=17 cases) (MGUS-like profile). As controls, newly-diagnosed MGUS (n=23) and symptomatic MM (n=23; MM-s), as well as 10 age-matched healthy adult (HA) volunteers undergoing orthopedic surgery, were studied. All control and patient samples were collected after informed consent was given by each individual, according to the local ethic committees and the Helsinki Declaration protocol. Most LTDC-MM patients (90%) were enrolled in the GEM 2000 protocol, therefore receiving 6 induction cycles of VBMC/VBAD followed by HDT/ASCT and maintenance with interferon/prednisone. At the moment of the present study, 85% of these patients were off any anti-myeloma therapy for > 4 years. Median time from diagnosis was 9 years (range, 5 to 20 years). The study was conducted on paired BM and PB samples collected at the same time for each individual including all patient and control groups.
Overall, a total of 168 samples were obtained with the following distribution per group: Figure 3A ), as described previously. 17, [19] [20] [21] In all cases, data acquisition was performed in a FACSCanto II flow cytometer (BDB) using the FACSDiva software (version 6.1, BDB) for ≥ 10 6 leukocytes/tube using the EuroFlow instrument setup data acquisition standard operating procedures. 22 For data analysis the INFINICYT software (Cytognos SL, Salamanca, Spain) was used.
Statistical Methods
The number of PB cell populations was recorded as absolute number of cells/µl while BM cell populations were described as percentages from all BM nucleated cells, after correcting for the PC infiltration levels. For all parameters, median and mean values (and their standard deviation) and range, were calculated. The Mann-Whitney U test was used to evaluate the statistical significance of differences observed between groups. For all statistical analysis the SPSS software package (version 15.0, SPSS, Inc., Chicago, IL, USA), was used.
Results
Distribution of distinct populations of effector cells and regulatory T cells in PB and BM
The CD4 + /CD8 + ratio was significantly lower, both in PB and BM of LTDC-MM as compared to HA (p≤.0001), MGUS (p≤.05) and also MM-s (p≤.008) ( Figure 4A ). This 
Distribution of B cell populations in PB and BM
The total PB and BM B-cell counts from LTDC-MM patients were within the normal range (similar to those found in HA), but significantly higher than those observed in MGUS PB (p=.04) and in MM-s PB and BM (p=.004 and p=.005, respectively) ( Figure   3B ). A similar pattern was also found for the distribution of B-cell precursors in the BM of LTDC-MM vs. MM-s (p=.002) ( Figure 3C ). In depth analysis of the different subsets of PB B-cells (immature, naïve and memory B-lymphocytes plus plasmablasts/PC)
showed that the pre-germinal center cell subsets (e.g. immature and naïve Blymphocytes) were present in LTDC-MM at similar values to those of HA, while 9 increased with respect to MGUS (p=.01 and p=.006 respectively) and MM-s (p=.01 and p=.0001, respectively). Conversely, no differences were detected in PB for memory Bcells and plasmablasts/PCs, among the three groups ( Figure 3C ). Despite this, the number of terminally differentiated normal BM PCs was significantly increased in LTDC-MM vs. MM-s (p=.002), with similar values to those of MGUS patients (p=.6), but still reduced when compared to HA (p=.03).
Distribution of circulating tissue macrophages (TiMas) and dendritic cells (DC) in PB and BM
The overall DC counts in PB and BM were similar in LTDC-MM, MGUS, MM-s and HA.
However, a more detailed analysis of the distinct subsets of DC and TiMas showed a significantly different composition of this cell compartment in LTDC-MM vs. MM-s patients ( Figures 2B and 2C ). Accordingly, LTDC-MM patients showed higher percentages of plasmacytoid-DCs (p=.05) in both PB and BM, as well as of myeloidDCs (p=.01) in PB; by contrast, the number of TiMas was decreased in both the BM (p=.06) and PB (p=.02) of these patients. Overall, these differences were associated with a recovery of the normal distribution of PB DCs and TiMas in LTDC-MM patients towards similar levels to those found in HA (p>.05). Nevertheless, differences were still noted between LTDC-MM and HA for BM TiMas (p=.03) and p-Dcs (p=.03). In addition, we stratified LTDC-MM patients into those achieving CR (n=11) versus those in near CR or partial response (MGUS-profile; n=17). Similarly to the former comparison, no major differences were found in the distribution of PB T, B, NK and DC between the groups (Table 2) .
Distribution of lymphoid cells and DC in LTDC-
Finally, we investigated whether the duration of remission in LTDC-MM patients was associated with specific changes in the immune system, by comparing patients with ≥ 10 years disease control (n=7) versus patients with 5-10 years follow-up (n=21). Our results showed that the former cohort had increased counts in PB of total T-cells (p=.004) including both the CD4+ (p=.001) and CD8+ (p=.008) subsets, naïve B-cells (p=.04), and myeloid-DCs (p=.03) ( Table 2) .
Discussion
Despite the fact that until recently MM was considered incurable, the introduction of HDT/ASCT and novel drugs has made possible for a small fraction of patients to attain long-term (≥5 years) disease control even in the absence of CR, after reverting to an MGUS-like profile. The knowledge about the underlying mechanisms leading to disease suppression in these patients are largely unknown, although immunesurveillance has been hypothesized to play a critical role.
In this exploratory study, we analyzed the distribution of the most representative 
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